Abivax is focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. We believe our lead drug candidate obefazimod has the potential to be meaningfully differentiated from currently available treatments in IBD:
Abivax SA has been listed on Euronext Paris since 26 June 2015 and on the Nasdaq Global Market since October 20, 2023.
Existing treatments have left substantial patient populations suffering from inflammatory bowel diseases with significant unmet medical needs for novel therapies with durable efficacy, improved safety profiles and easy oral administration. We believe our lead drug candidate obefazimod has the potential to address the current limitations. Obefazimod is currently being developed with a defined path to market in global Phase 3 clinical trials for potential first-line advanced therapy for moderately to severely active ulcerative colitis. We have an international and highly experienced executive and governance team and are backed by top-tier U.S. and European investors as well as renowned Key Opinion Leaders in the IBD field.